Taj Worldwide | Taj Group | Media | Career | FAQs | Feedback | contact us
 
Taj Logo
 
Quality Medicines Api Generic Manufacturing For Doctors Brands Newsroom
 

 
HOME >> PRODUCTS >> Meterra
Taj  ALL Products View Products According to Category


DRUG DESCRIPTION

Meterra is designed as a capsule for once-a-day oral administration.Meterra capsules contain 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, and 70 mg of lisdexamfetamine dimesylate and the following inactive ingredients: microcrystalline cellulose, croscarmellose sodium, and magnesium stearate.

INDICATIONS
Attention Deficit Hyperactivity Disorder

METERRA ® (LISDEXAMFETAMINE DIMESYLATE) IS A PRESCRIPTION MEDICINE USED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) IN PATIENTS 6 YEARS AND ABOVE, AND FOR THE TREATMENT OF MODERATE TO SEVERE BINGE EATING DISORDER (B.E.D.) IN ADULTS. METERRA IS NOT FOR WEIGHT LOSS. IT IS NOT KNOWN IF METERRA IS SAFE AND EFFECTIVE FOR THE TREATMENT OF OBESITY.

IMPORTANT SAFETY INFORMATION
Meterra® is a federally controlled substance (CII) because it can be abused or lead to dependence. Keep Meterra in a safe place to prevent misuse and abuse. Selling or giving away Meterra may harm others and is against the law.
Meterra is a stimulant medicine. Tell the doctor if you or your child have ever abused or been dependent on alcohol, prescription medicines, or street drugs.
Who should not take Meterra?
Do not take Meterra if you or your child are:
• taking or has taken an anti-depression medicine called a monoamine oxidase inhibitor (MAOI) within the past 14 days.
• sensitive or allergic to, or had a reaction to other stimulant medicines.
Problems that can occur while taking Meterra. Tell the doctor:
• if you or your child have heart problems or heart defects, high blood pressure, or a family history of these problems. This is important because sudden death has occurred in people with heart problems or defects taking stimulant medicines, and sudden death, stroke and heart attack have happened in adults taking stimulant medicines. Since increases in blood pressure and heart rate may occur, the doctor should regularly check these during treatment. Call the doctor right away if you or your child have any signs of heart problems such as chest pain, shortness of breath, or fainting while taking Meterra.
• if you or your child have mental problems, or a family history of suicide, bipolar illness, or depression. This is important because new or worsening behavior and thought problems or bipolar illness may occur. New symptoms such as seeing or hearing things that are not real, believing things that are not true, being suspicious, or having new manic symptoms may occur. Call the doctor right away if there are any new or worsening mental symptoms during treatment.
• if you or your child have circulation problems in fingers and toes (peripheral vasculopathy, including Raynaud’s phenomenon). Fingers or toes may feel numb, cool, painful, sensitive to temperature and/or change color from pale, to blue, to red. Call the doctor right away if any signs of unexplained wounds appear on fingers or toes while taking Meterra.
• if your child is having slowing of growth (height and weight); Meterra may cause this serious side effect. Your child should have his or her height and weight checked often while taking Meterra. The doctor may stop treatment if a problem is found during these check-ups.
• if you or your child are pregnant or plan to become pregnant. It is not known if Meterra may harm your unborn baby.
• if you or your child are breastfeeding or plan to breastfeed. Do not breastfeed while taking Meterra. Talk to your doctor about the best way to feed your baby if you take Meterra.
What are possible side effects of Meterra?
The most common side effects of Meterra reported in ADHD studies include:
o anxiety
o decreased appetite
o diarrhea
o dizziness
o dry mouth
o irritability
o loss of appetite
o nausea
o trouble sleeping
o upper stomach pain
o vomiting
o weight loss
The most common side effects of Meterra reported in adults with moderate to severe BED include:
o dry mouth
o trouble sleeping
o decreased appetite
o increased heart rate
o constipation
o feeling jittery
o anxiety



DOSAGE AND ADMINISTRATION
Dosage should be individualized according to the therapeutic needs and response of the patient. Meterra should be administered at the lowest effective dosage.

In children 6 to12 years of age or adults who are either starting treatment for the first time or switching from another medication, 30 mg once daily in the morning is the recommended dose. If the decision is made in the judgment of the clinician to increase the dose beyond 30 mg/day, daily dosage may be adjusted in increments of 10 mg or 20 mg at approximately weekly intervals. The maximum recommended dose is 70 mg/day; doses greater than 70 mg/day of Meterra have not been studied. Amphetamines are not recommended for children under 3 years of age. Meterra has not been studied in children under 6 years of age or over 12 years of age.

Meterra should be taken in the morning. Afternoon doses should be avoided because of the potential for insomnia.

Meterra may be taken with or without food.

Meterra capsules may be taken whole, or the capsule may be opened and the entire contents dissolved in a glass of water. The solution should be consumed immediately and should not be stored. The dose of a single capsule should not be divided. The contents of the entire capsule should be taken, and patients should not take anything less than one capsule per day.

SIDE EFFECTS
Weight Loss – In the controlled adult trial, mean weight loss after 4 weeks of therapy was 2.8 lbs, 3.1 lbs, and 4.3 lbs, for patients receiving final doses of 30 mg, 50 mg, and 70 mg of Meterra, respectively, compared to a mean weight gain of 0.5 lbs for patients receiving placebo.

Cardiac Disorders – palpitation

Eye Disorders – vision blurred, mydriasis, diplopia

Immune System Disorders – hypersensitivity

Nervous System Disorders – seizure, dyskinesia

Psychiatric Disorder – psychotic episodes, mania, hallucination, depression, aggression, dysphoria, euphoria, logorrhea

Skin and Subcutaneous Tissue Disorder – angioedema, urticaria Adverse Reactions Associated with the Use of Amphetamine
Cardiovascular

Palpitations, tachycardia, elevation of blood pressure, sudden death, myocardial infarction. There have been isolated reports of cardiomyopathy associated with chronic amphetamine use.

Central Nervous System - Psychotic episodes at recommended doses, overstimulation, restlessness, dizziness, insomnia, euphoria, dyskinesia, dysphoria, depression, tremor, headache, exacerbation of motor and phonic tics and Tourette's syndrome, seizures, stroke.

Gastrointestinal - Dryness of the mouth, unpleasant taste, diarrhea, constipation, other gastrointestinal disturbances.

Allergic - Urticaria, rashes, and hypersensitivity reactions, including angioedema and anaphylaxis. Serious skin reactions, including Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis have been reported.

Endocrine - Impotence, changes in libido.

WARNINGS
Serious Cardiovascular Events
Sudden Death and Pre-existing Structural Cardiac Abnormalities or Other Serious Heart Problems

Children and Adolescents
Sudden death has been reported in association with CNS stimulant treatment at usual doses in children and adolescents with structural cardiac abnormalities or other serious heart problems. Although some serious heart problems alone carry an increased risk of sudden death, stimulant products generally should not be used in children or adolescents with known serious structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, or other serious cardiac problems that may place them at increased vulnerability to the sympathomimetic effects of a stimulant drug [see CONTRAINDICATIONS].

Adults
Sudden death, stroke, and myocardial infarction have been reported in adults taking stimulant drugs at usual doses for ADHD. Although the role of stimulants in these adult cases is unknown, adults have a greater likelihood than children of having serious structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, or other serious cardiac problems. Adults with such abnormalities should also generally not be treated with stimulant drugs [see CONTRAINDICATIONS].

CONTRAINDICATIONS
* Advanced arteriosclerosis, symptomatic cardiovascular disease, moderate to severe hypertension, hyperthyroidism, known hypersensitivity or idiosyncratic reaction to sympathomimetic amines, glaucoma
* Agitated states
* Patients with a history of drug abuse
* During or within 14 days following the administration of monoamine oxidase inhibitors (hypertensive crises may result)

Presentation
Meterra Capsules                 
Blister of 10 Capsules






Note :
This product information is intended only for residents of the India. Taj Pharmaceuticals Limited,  medicines help to treat and prevent a range of conditions—from the most common to the most challenging—for people around the world.

Information for Health Care Professionals

*** Please consult local Prescribing Information for any product before use. This website is an international information resource for healthcare professionals with an interest in disease management. This website is not intended to replace the advice of a qualified healthcare professional. Above brand is a trademark of the Taj group of companies (Taj Pharmaceuticals Limited).

 

 

 


Treatment of Attention
Deficit Hyperactivity Disorder

 

    Meterra ® Taj Products
Product Gallery
PDF Download
Doc Download
MSDS Download
COA Download
 Prescription Products (Rx)
 
Attention Deficit Hyperactivity Disorder

 









 

 
 
 

 

 


 

 

 

 

 

 

 

 

 


 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

              
 Print page   Send by mail

 

 

 

 

 

 

 

 

 

 

 

 

   
   
PRODUCTS
 
 
   
   
   
  india flag
  The Taj Pharmaceuticals Limited (Taj Group) has operations in every major international market
    AFRICA
  ASIA PACIFIC
  EUROPE
  MIDDLE EAST
  THAILAND
  BANGLADESH
  NORTH AMERICA
  SOUTH AMERICA
  RUSSIA
  NEWZELAND
  UNITED KINGDOM
 

   

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 



 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 
 www.tajpharma.com

   

 

About Taj

Company

Products Diseases Health Divisions Media R & D Sustainability
Figure & Reports Investors

Countries

Brochure E-mail us Export & Import
Vacancies | C & F Agency | Distributor | Group Companies | History | Enquire Form | Countries | Pharma Technology
 Contact | Sitemap | User Terms and Conditions | Privacy and Cookie Statement